BioCentury | Apr 6, 2021
Distillery Therapeutics

Herb-extracted compound triptonide identified as male contraceptive

...Province, Guangzhou, Chinaemail: tyg813@126.comCONTACT: Wei Yan, University of Nevada, Reno School of Medicine, Reno, Nev.; Lundquist Institute, Torrance, Calif.; University of California Los Angeles...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...is with the University of California San Francisco; Autobahn has a prior arrangement with the University of California Los Angeles.Separately...
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

...Ministry of Science and Technology (MOST) announced that two high-profile cross-border genomics partnerships, one between University of California Los Angeles...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset: Guest Commentary

...Inc. and a visiting scholar at the UCLA...
BioCentury | Sep 22, 2020
Management Tracks

Recent crackdowns on export regulations in China may provide clues into ongoing GenScript investigations

...and Ministry of Science and Technology (MOST) announced that two high-profile cross-border genomics partnerships, one between University of California Los Angeles...
BioCentury | Sep 9, 2020
Politics & Policy

Impact of China’s export restrictions on biopharma dealmaking likely limited, at least for now

...to the announcement by MOST in 2018 that two high profile cross-border genomics partnerships, by University of California Los Angeles (UCLA)...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Repurposed integrin inhibitor for cardiac wound healing

...July 3, 2020doi:10.1016/j.cell.2020.06.030CONTACT: Arjun Deb, University of California Los Angeles, Los Angeles, Calif.email: adeb@mednet.ucla.edu Claire Quang Impetreve, cilengitide (EMD 121974, nsc 707544) University of California Los Angeles Cardiovascular Myocardial...
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

...I/II study to treat solid tumors in early 2021. Smartwatch PK monitoring Stanford University and University of California Los Angeles...
...Writer TScan Therapeutics Inc. Icahn School of Medicine at Mount Sinai University of North Carolina at Chapel Hill Stanford University University of California Los Angeles T3...
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

...Inc., said the concept of aging clocks first emerged in a 2013 paper in which University of California Los Angeles...
...cellular aging (see “Fountain Therapeutics: an AI-based Platform to Reverse Cellular Aging” ). Danielle Golovin, Staff Writer University of California Los Angeles Insilico...
BioCentury | Jun 25, 2020
Finance

Autobahn Labs bringing industrial translation to academic projects via joint ownership model, starting with UCLA

...Biocapital, Evotec SE and the family investment fund KCK Ltd., Autobahn announced a partnership with University of California Los Angeles...
...university collaborations. CSO Thomas Novak said Autobahn will work with tech transfer offices such as UCLA’s...
Items per page:
1 - 10 of 514
BioCentury | Apr 6, 2021
Distillery Therapeutics

Herb-extracted compound triptonide identified as male contraceptive

...Province, Guangzhou, Chinaemail: tyg813@126.comCONTACT: Wei Yan, University of Nevada, Reno School of Medicine, Reno, Nev.; Lundquist Institute, Torrance, Calif.; University of California Los Angeles...
BioCentury | Dec 22, 2020
Deals

Dec. 21-23 Deals Quick Takes: Cytokinetics regains European rights to heart failure program; plus Boehringer-Epizyme, Vertex-Skyhawk, Lilly-Prevail, GSK-Sosei Heptares, ImmunityBio-NantKwest and more

...is with the University of California San Francisco; Autobahn has a prior arrangement with the University of California Los Angeles.Separately...
BioCentury | Nov 6, 2020
Management Tracks

BeiGene’s pathfinding CFO Liang to retire

...Ministry of Science and Technology (MOST) announced that two high-profile cross-border genomics partnerships, one between University of California Los Angeles...
BioCentury | Oct 22, 2020
Politics, Policy & Law

Protecting biomedical innovation as a national security asset: Guest Commentary

...Inc. and a visiting scholar at the UCLA...
BioCentury | Sep 22, 2020
Management Tracks

Recent crackdowns on export regulations in China may provide clues into ongoing GenScript investigations

...and Ministry of Science and Technology (MOST) announced that two high-profile cross-border genomics partnerships, one between University of California Los Angeles...
BioCentury | Sep 9, 2020
Politics & Policy

Impact of China’s export restrictions on biopharma dealmaking likely limited, at least for now

...to the announcement by MOST in 2018 that two high profile cross-border genomics partnerships, by University of California Los Angeles (UCLA)...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Repurposed integrin inhibitor for cardiac wound healing

...July 3, 2020doi:10.1016/j.cell.2020.06.030CONTACT: Arjun Deb, University of California Los Angeles, Los Angeles, Calif.email: adeb@mednet.ucla.edu Claire Quang Impetreve, cilengitide (EMD 121974, nsc 707544) University of California Los Angeles Cardiovascular Myocardial...
BioCentury | Aug 1, 2020
Translation in Brief

TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

...I/II study to treat solid tumors in early 2021. Smartwatch PK monitoring Stanford University and University of California Los Angeles...
...Writer TScan Therapeutics Inc. Icahn School of Medicine at Mount Sinai University of North Carolina at Chapel Hill Stanford University University of California Los Angeles T3...
BioCentury | Jul 22, 2020
Emerging Company Profile

Deep Longevity: Insilico spinout clocks biological age

...Inc., said the concept of aging clocks first emerged in a 2013 paper in which University of California Los Angeles...
...cellular aging (see “Fountain Therapeutics: an AI-based Platform to Reverse Cellular Aging” ). Danielle Golovin, Staff Writer University of California Los Angeles Insilico...
BioCentury | Jun 25, 2020
Finance

Autobahn Labs bringing industrial translation to academic projects via joint ownership model, starting with UCLA

...Biocapital, Evotec SE and the family investment fund KCK Ltd., Autobahn announced a partnership with University of California Los Angeles...
...university collaborations. CSO Thomas Novak said Autobahn will work with tech transfer offices such as UCLA’s...
Items per page:
1 - 10 of 514